Obstetrics and Gynaecology, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Arch Gynecol Obstet. 2023 Oct;308(4):1085-1091. doi: 10.1007/s00404-023-06941-w. Epub 2023 Feb 4.
Administration of antenatal corticosteroids (ACS) for accelerating foetal lung maturation in threatened preterm birth is one of the cornerstones of prevention of neonatal mortality and morbidity. To identify the optimal timing of ACS administration, most studies have compared subgroups based on treatment-to-delivery intervals. Such subgroup analysis of the first placebo-controlled randomised controlled trial indicated that a one to seven day interval between ACS administration and birth resulted in the lowest rates of neonatal respiratory distress syndrome. This efficacy window was largely confirmed by a series of subgroup analyses of subsequent trials and observational studies and strongly influenced obstetric management. However, these subgroup analyses suffer from a methodological flaw that often seems to be overlooked and potentially has important consequences for drawing valid conclusions. In this commentary, we point out that studies comparing treatment outcomes between subgroups that are retrospectively identified at birth (i.e. after randomisation) may not only be plagued by post-randomisation confounding bias but, more importantly, may not adequately inform decision making before birth, when the projected duration of the interval is still unknown. We suggest two more formal interpretations of these subgroup analyses, using a counterfactual framework for causal inference, and demonstrate that each of these interpretations can be linked to a different hypothetical trial. However, given the infeasibility of these trials, we argue that none of these rescue interpretations are helpful for clinical decision making. As a result, guidelines based on these subgroup analyses may have led to suboptimal clinical practice. As an alternative to these flawed subgroup analyses, we suggest a more principled approach that clearly formulates the question about optimal timing of ACS treatment in terms of the protocol of a future randomised study. Even if this 'target trial' would never be conducted, its protocol may still provide important guidance to avoid repeating common design flaws when conducting observational 'real world' studies using statistical methods for causal inference.
产前皮质类固醇(ACS)的应用可加速有早产风险的胎儿肺成熟,是预防新生儿死亡率和发病率的基石之一。为了确定 ACS 给药的最佳时机,大多数研究都是基于治疗到分娩的时间间隔来比较亚组。首次安慰剂对照随机临床试验的亚组分析表明,ACS 给药与分娩之间的 1-7 天间隔可使新生儿呼吸窘迫综合征的发生率最低。随后的试验和观察性研究的一系列亚组分析在很大程度上证实了这一疗效窗口,并强烈影响了产科管理。然而,这些亚组分析存在一个方法学缺陷,通常似乎被忽视了,并且对得出有效结论可能具有重要影响。在这篇评论中,我们指出,在出生时(即在随机分组后)回顾性地确定治疗结果的亚组之间进行的研究,不仅可能受到随机分组后混杂偏倚的影响,而且更重要的是,可能无法在出生前提供充分的决策信息,因为预计间隔时间仍然未知。我们使用因果推理的反事实框架对这些亚组分析提出了两种更正式的解释,并证明这两种解释都可以与不同的假设试验相关联。然而,考虑到这些试验的不可行性,我们认为这些救援解释对于临床决策都没有帮助。因此,基于这些亚组分析的指南可能导致了次优的临床实践。作为对这些有缺陷的亚组分析的替代方法,我们建议采用一种更有原则的方法,根据未来随机研究的方案,明确提出 ACS 治疗最佳时机的问题。即使该“目标试验”永远不会进行,其方案仍可能为使用因果推断的统计方法进行观察性“真实世界”研究提供重要指导,以避免重复常见的设计缺陷。